Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics Inc (NQ: IKT )

1.370 -0.100 (-6.81%)
Streaming Delayed Price Updated: 12:54 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,220
Open 1.430
Bid (Size) 1.360 (3)
Ask (Size) 1.370 (2)
Prev. Close 1.470
Today's Range 1.370 - 1.450
52wk Range 0.7900 - 4.181
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Performance

YTD
+2.86%
+2.86%
1 Month
-36.58%
-36.58%
3 Month
-56.51%
-56.51%
6 Month
+54.67%
+54.67%
1 Year
-58.50%
-58.50%

More News

Read More
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics: Q3 Earnings Insights
Via Benzinga
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Inhibikase Therapeutics
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
Via Benzinga
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
From Inhibikase Therapeutics
Via GlobeNewswire
Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
Via NewMediaWire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
From Inhibikase Therapeutics
Via GlobeNewswire
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
From Inhibikase Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.